Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

70.65USD
25 Sep 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$70.65
Open
--
Day's High
--
Day's Low
--
Volume
2,047
Avg. Vol
8,757,226
52-wk High
$71.57
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $187,895.50
Shares Outstanding(Mil.): 2,659.52
Dividend: 0.48
Yield (%): 2.72

Financials

  MRK Industry Sector
P/E (TTM): 48.50 30.67 32.94
EPS (TTM): 1.46 -- --
ROI: 5.65 13.17 12.84
ROE: 10.95 15.10 14.95

Merck's Frazier to remain CEO beyond 2019

Merck & Co Inc's Kenneth Frazier will stay on as chief executive beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEO to retire at the age of 65.

7:23am EDT

UPDATE 1-Merck's Frazier to remain CEO beyond 2019

Sept 26 Merck & Co Inc's Kenneth Frazier will stay on as chief executive beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEO to retire at the age of 65.

7:20am EDT

Merck CEO to stay post 65 after company amends retirement policy

Sept 26 Drugmaker Merck and Co Inc said on Wednesday that its board voted to rescind a policy requiring its head to retire at 65, a move that will permit current Chief Executive Officer Kenneth Frazier to remain in the role beyond next year.

6:55am EDT

Roche's Tecentriq, trailing rival drugs, lifts lung cancer survival

ZURICH A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, according to a study, aiding the Swiss group's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Sep 25 2018

UPDATE 1-Roche's Tecentriq, trailing rival drugs, lifts lung cancer survival

* Rivals Keytruda, Opdivo have overshadowed Roche drug (Adds comment from company, market reaction, comment from analyst)

Sep 25 2018

Roche's Tecentriq adds 2 months to lung cancer patients' lives - study

ZURICH, Sept 25 A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, potentially aiding the Swiss company's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Sep 25 2018

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

Sep 10 2018

Merck's Keytruda clocks up new win as EU approves chemo cocktail

LONDON, Sept 10 Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further advance for the product after uncertainty about its EU prospects a year ago.

Sep 10 2018

Factbox: Challenges facing German pharmaceutical company Bayer

FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.

Sep 04 2018

FDA approves two new HIV drugs from Merck

Merck & Co Inc said on Thursday the U.S. Food And Drug Administration approved two of its HIV oral drugs, nearly two months ahead of schedule.

Aug 30 2018

Earnings vs. Estimates